Search Results

There are 1576739 results for: content related to: Targeted therapy in pediatric and adolescent oncology

  1. Oral Chemotherapeutic Agents

    Standard Article

    Encyclopedia of Drug Metabolism and Interactions

    Shin Ogita, Patricia LoRusso and Jing Li

    Published Online : 15 MAY 2012, DOI: 10.1002/9780470921920.edm132

  2. You have free access to this content
    Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 2, 15 January 2012, Pages: 300–311, Jerald P. Radich

    Article first published online : 29 JUN 2011, DOI: 10.1002/cncr.26280

  3. You have free access to this content
    Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

    Cancer

    Volume 116, Issue 6, 15 March 2010, Pages: 1419–1430, Hagop M. Kantarjian, Jorge Cortes, Paul La Rosée and Andreas Hochhaus

    Article first published online : 29 JAN 2010, DOI: 10.1002/cncr.24928

  4. Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment options

    Journal of Surgical Oncology

    Volume 104, Issue 8, 15 December 2011, Pages: 888–895, Megan V. Caram and Scott M. Schuetze

    Article first published online : 8 NOV 2011, DOI: 10.1002/jso.21930

  5. Human hepatocyte assessment of imatinib drug–drug interactions – complexities in clinical translation

    British Journal of Clinical Pharmacology

    Volume 80, Issue 5, November 2015, Pages: 1097–1108, Jan H. Beumer, Venkateswaran C. Pillai, Robert A. Parise, Susan M. Christner, Brian F. Kiesel, Michelle A. Rudek and Raman Venkataramanan

    Article first published online : 19 SEP 2015, DOI: 10.1111/bcp.12723

  6. You have full text access to this OnlineOpen article
    Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants

    Cancer Science

    Volume 105, Issue 1, January 2014, Pages: 117–125, Jie Zhao, Haitian Quan, Yongping Xu, Xiangqian Kong, Lu Jin and Liguang Lou

    Article first published online : 4 JAN 2014, DOI: 10.1111/cas.12320

  7. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells

    Journal of Cellular Physiology

    Volume 205, Issue 2, November 2005, Pages: 218–227, Faye M. Johnson, Babita Saigal and Nicholas J. Donato

    Article first published online : 10 MAY 2005, DOI: 10.1002/jcp.20383

  8. Pharmacokinetic Impact of SLCO1A2 Polymorphisms on Imatinib Disposition in Patients With Chronic Myeloid Leukemia

    Clinical Pharmacology & Therapeutics

    Volume 90, Issue 1, July 2011, Pages: 157–163, Y Yamakawa, A Hamada, T Shuto, M Yuki, T Uchida, H Kai, T Kawaguchi and H Saito

    Article first published online : 1 JUN 2011, DOI: 10.1038/clpt.2011.102

  9. Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment

    Biotechnology and Bioengineering

    Volume 107, Issue 5, 1 December 2010, Pages: 884–893, Liliana S. Mendonça, João N. Moreira, Maria C. Pedroso de Lima and Sérgio Simões

    Article first published online : 14 JUL 2010, DOI: 10.1002/bit.22858

  10. Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 12, December 2014, Pages: 3810–3833, Jie Shao, John S. Markowitz, Di Bei and Guohua An

    Article first published online : 10 OCT 2014, DOI: 10.1002/jps.24113

  11. Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest

    Cell Biology International

    Volume 39, Issue 8, August 2015, Pages: 923–932, Mariko Morii, Yasunori Fukumoto, Sho Kubota, Noritaka Yamaguchi, Yuji Nakayama and Naoto Yamaguchi

    Article first published online : 27 APR 2015, DOI: 10.1002/cbin.10460

  12. You have free access to this content
    Controversies in the management of gastrointestinal stromal tumors

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue 3, September 2014, Pages: 216–227, Desmond Yip, John Zalcberg, Stephen Ackland, Andrew P Barbour, Jayesh Desai, Stephen Fox, Dusan Kotasek, Grant McArthur and B Mark Smithers

    Article first published online : 27 MAR 2014, DOI: 10.1111/ajco.12187

  13. You have free access to this content
    Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management

    American Journal of Hematology

    Volume 90, Issue 3, March 2015, Pages: 250–262, Animesh Pardanani

    Article first published online : 17 FEB 2015, DOI: 10.1002/ajh.23931

  14. You have free access to this content
    Practical management of patients with chronic myeloid leukemia

    Cancer

    Volume 117, Issue 19, 1 October 2011, Pages: 4343–4354, Francisco Cervantes and Michael Mauro

    Article first published online : 16 MAR 2011, DOI: 10.1002/cncr.26062

  15. You have full text access to this OnlineOpen article
    The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice

    Physiological Reports

    Volume 3, Issue 11, November 2015, R. Scott Stephens, Laura Johnston, Laura Servinsky, Bo S. Kim and Mahendra Damarla

    Article first published online : 30 NOV 2015, DOI: 10.14814/phy2.12589

  16. Surveillance strategies for gastrointestinal stromal tumors

    Journal of Surgical Oncology

    Volume 104, Issue 8, 15 December 2011, Pages: 921–927, Travis E. Grotz and John H. Donohue

    Article first published online : 8 NOV 2011, DOI: 10.1002/jso.21862

  17. Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite

    Clinical Pharmacology & Therapeutics

    Volume 94, Issue 3, September 2013, Pages: 383–393, A M Filppula, A Tornio, M Niemi, P J Neuvonen and J T Backman

    Article first published online : 8 MAY 2013, DOI: 10.1038/clpt.2013.92

  18. You have free access to this content
    Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

    Cancer

    Volume 115, Issue 18, 15 September 2009, Pages: 4136–4147, Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, Saengsuree Jootar, Jerzy Holowiecki, Nelson Hamerschlak, Timothy Hughes, Eric Bleickardt, David Dejardin, Jorge Cortes and Neil P. Shah

    Article first published online : 17 JUN 2009, DOI: 10.1002/cncr.24504

  19. You have full text access to this OnlineOpen article
    Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 69–81, Tim H. Brümmendorf, Jorge E. Cortes, Cármino Antonio de Souza, Francois Guilhot, Ladan Duvillié, Dmitri Pavlov, Karïn Gogat, Athena M. Countouriotis and Carlo Gambacorti-Passerini

    Article first published online : 8 SEP 2014, DOI: 10.1111/bjh.13108

  20. You have free access to this content
    Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors

    International Journal of Cancer

    Volume 129, Issue 11, 1 December 2011, Pages: 2533–2542, Burton L. Eisenberg and Jonathan C. Trent

    Article first published online : 28 SEP 2011, DOI: 10.1002/ijc.26234